<DOC>
	<DOCNO>NCT00968942</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy 2 sequential dos RT001 compare placebo gel treat moderate severe lateral canthal line adult .</brief_summary>
	<brief_title>Efficacy Safety Study RT001 Treat Moderate Severe Lateral Canthal Lines</brief_title>
	<detailed_description>This double-blind , randomize , parallel-group , control , repeat dose , single center study evaluate efficacy safety repeat application RT001 compare placebo gel least 36 subject moderate severe lateral canthal line ( LCL ) . Subjects randomized 1 2 treatment group 1:1 ratio ( active versus placebo ) . At least 36 adult volunteer provide informed consent meet study eligibility criterion enrol . There 18 subject treatment group .</detailed_description>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Female male , 30 60 year age Bilateral lateral canthal line rat moderate severe Willing refrain receive facial filler , laser treatment , use product affect skin remodel product may cause active dermal response treatment area begin Screening End Study Women childbearing potential must practice willing continue use effective method birth control course study Any neurological condition may place subject increase risk exposure Botulinum Toxin Type A , include peripheral motor neuropathic disease amyotrophic lateral sclerosis motor neuropathy , neuromuscular junctional disorder Muscle weakness paralysis area receive study treatment Active skin disease irritation treatment area Eyelid ptosis , excessive dermatochalasis , deep dermal scar inability substantially lessen lateral canthal line treat physically spread apart Use prescription retinoid product past 3 month prior Screening Chemical peel ( medium depth deep ) past 9 month prior Screening Undergone procedure may affect lateral canthal region : periorbital surgery , brow lift related procedure , laser skin resurface soft tissue augmentation ( upper half face ) past 12 month prior Screening Screening electrocardiogram ( ECG ) abnormal clinically significant history hypokalemia , torsade de pointe , unstable angina , myocardial infarction congestive heart failure family history prolong QT Previous treatment Botulinum Toxin Type A face area Previous treatment great 200 U Botulinum Toxin Type A anywhere else body within last 6 month prior Screening Concurrent use aminoglycoside antibiotic , agent might interfere neuromuscular transmission start Screening Use topical steroid either treatment area use medication suppress immune system 30 day prior Screening continue End Study Clinically significant laboratory value Screening</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Lateral Canthal Lines</keyword>
	<keyword>Crow 's Feet</keyword>
	<keyword>Facial Wrinkles</keyword>
</DOC>